Scilex Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Scilex Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013537
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Scilex Pharmaceuticals Inc (Scilex Pharma), a subsidiary of Sorrento Therapeutics Inc is a developer of pharmaceutical products. The company develops and commercializes branded pharmaceutical products for the treatment of pain. Its technologies include drug delivery and proprietary patch technologies. Scilex Pharma’s lead product under development, ZTlido, a lidocaine patch formulation for the treatment of relieving the pain of postherpetic neuralgia. The company also provides patch technology that utilizes a proprietary single layer anhydrous system. Scilex Pharma is headquartered in Malvern, Pennsylvania, the US.

Scilex Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Scilex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Scilex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Scilex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Scilex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Scilex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Scilex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Scilex Pharma Raises USD0.5 Million in Financing 10
Scilex Pharma Raises US$5 Million In Venture Financing 11
Equity Offering 12
Scilex Pharma Raises USD5 Million in Private Placement Of Shares And Warrants 12
Acquisition 13
Sorrento Therapeutics Acquires 72% Stake in Scilex Pharma for USD47.6 Million 13
Itochu Chemical Frontier Invests in Scilex Pharma 14
Scilex Pharmaceuticals Inc – Key Competitors 15
Scilex Pharmaceuticals Inc – Key Employees 16
Scilex Pharmaceuticals Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Product News 18
12/05/2016: Sorrento Subsidiary, SCILEX Pharmaceuticals Announces Key Endpoints Met in Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido 18
05/12/2016: SCILEX Pharmaceuticals Study Suggests Underutilization of Recommended First-Line Lidocaine Patches and Opioid Overuse for Treatment of Pain Associated with Post-Herpetic Neuralgias 19
04/22/2016: SCILEX Pharmaceuticals Reports First-Line Treatments Including Lidocaine Patches for Post-Herpetic Neuralgia Are Significantly Underutilized 20
Feb 23, 2016: SCILEX Pharmaceuticals Announces Senior Industry Hires 21
01/09/2017: Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Scilex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Scilex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Scilex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Scilex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Scilex Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Scilex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Scilex Pharma Raises USD0.5 Million in Financing 10
Scilex Pharma Raises US$5 Million In Venture Financing 11
Scilex Pharma Raises USD5 Million in Private Placement Of Shares And Warrants 12
Sorrento Therapeutics Acquires 72% Stake in Scilex Pharma for USD47.6 Million 13
Itochu Chemical Frontier Invests in Scilex Pharma 14
Scilex Pharmaceuticals Inc, Key Competitors 15
Scilex Pharmaceuticals Inc, Key Employees 16

★海外企業調査レポート[Scilex Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Consolidated Edison Inc (ED)-エネルギー分野:企業M&A・提携分析
    Summary Consolidated Edison, Inc. (Con Edison) is an investor-owned energy company that offers wide range energy related products and services through its subsidiaries. It operates regulated electricity, gas and steam businesses, and competitive energy businesses. Con Edison’s competitive energy bus …
  • Stellar Biotechnologies Inc (SBOT):医療機器:M&Aディール及び事業提携情報
    Summary Stellar Biotechnologies Inc (Stellar Bio), formerly CAG Capital Inc is a provider of keyhole limpet hemocyanin proteins. The company offers potent immune-stimulating molecule used as an active pharmaceutical ingredient known as active immunotherapies or therapeutic vaccines and as an injecta …
  • Anadarko Petroleum Corp (APC):企業の財務・戦略的SWOT分析
    Anadarko Petroleum Corp (APC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • NorgesGruppen ASA:企業の戦略的SWOT分析
    NorgesGruppen ASA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • X4 Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary X4 Pharmaceuticals Inc (X4 Pharma) is a pharmaceutical company that develops novel therapeutics to treat cancer and rare diseases. The company’s lead drug candidate, X4P-001-LD, is in Phase 2/3 trial used for the treatment for patients with WHIM and other immunodeficiency disease. It also de …
  • Pt Indofood Sukses Makmur Tbk
    Pt Indofood Sukses Makmur Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Indofood Sukses Makmur Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Penske Automotive Group, Inc.:企業のM&A・事業提携・投資動向
    Penske Automotive Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Penske Automotive Group, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Bank of Ireland Group plc:企業のM&A・事業提携・投資動向
    Bank of Ireland Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of Ireland Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • VSE Corporation (VSEC):企業の財務・戦略的SWOT分析
    VSE Corporation (VSEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Dongbu Corporation:企業の戦略・SWOT・財務情報
    Dongbu Corporation - Strategy, SWOT and Corporate Finance Report Summary Dongbu Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Polpharma SA:企業の戦略的SWOT分析
    Polpharma SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • GeNeuro SA (GNRO):製薬・医療:M&Aディール及び事業提携情報
    Summary GeNeuro SA (GeNeuro) is a clinical stage pharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. The company provides treatments against inflammatory and degenerative disorders associated with endogenous retroviruses. GeNeuro develops therap …
  • The Real Good Food Company plc:戦略・SWOT・企業財務分析
    The Real Good Food Company plc - Strategy, SWOT and Corporate Finance Report Summary The Real Good Food Company plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Beach Energy Ltd (BPT):企業の財務・戦略的SWOT分析
    Beach Energy Ltd (BPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Centene Corp (CNC)-製薬・医療分野:企業M&A・提携分析
    Summary Centene Corp (Centene) is a healthcare service provider that offers services to government sponsored healthcare programs with focus on under-insured and uninsured individuals. It provides health plans through Medicaid, Medicare and Health Insurance Marketplace contracts; and other health sol …
  • Thrive Bioscience Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Thrive Bioscience Inc (Thrive Bioscience) is a life science company that provides automated non-microbial cell culture instruments. The company’s cell culture systems provide scalable cell propagation, analytics, reproducible protocols, and complete process history documentation with the ima …
  • Laurus Labs Ltd (LAURUSLABS):製薬・医療:M&Aディール及び事業提携情報
    Summary Laurus Labs Ltd (Laurus Labs) is a drug development company that manufactures active pharmaceutical ingredients. The company develops products through its business divisions such as laurus generics, ingredients and synthesis. It offers active pharmaceutical ingredients and intermediates for …
  • Optimum General Inc.:企業の戦略・SWOT・財務分析
    Optimum General Inc. - Strategy, SWOT and Corporate Finance Report Summary Optimum General Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Olin Corp (OLN):企業の財務・戦略的SWOT分析
    Olin Corp (OLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • New York Power Authority:電力:M&Aディール及び事業提携情報
    Summary New York Power Authority (NYPA) is a state-owned power organization. It generates electricity, and transmits and sells that on wholesale basis. The authority produces the electricity using hydro, gas, and oil sources. Through long-term electricity supply agreement with Astoria Energy II LLC, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆